Drug distributor Cardinal Health to lose OptumRx contracts

Go back to Drug distributor Cardinal Health to lose OptumRx contracts

Baird Defends Cardinal Health (CAH): 'Market fears played out, buyers on weakness'

April 23, 2024 6:21 AM EDT

Baird analyst Eric Coldwell reiterated an Outperform rating and $134.00 price target on Cardinal Health (NYSE: CAH).

The analyst comments "Market fears played out, buyers on weakness. We have long posited that CAH could well absorb loss of OptumRx given strong underlying market fundamentals,... More

Cardinal Health (CAH) shares down after losing OptumRx contracts

April 22, 2024 4:00 PM EDT

Shares of Cardinal Health (NYSE: CAH) fell 5% Monday after the company said that its contracts with UnitedHealth Group's (NYSE: UNH) OptumRx will not be renewed after they expire at the end of June.

Analysts from at least two firms believe that McKesson, a rival company, is likely... More